Filing Flows › Medifast (MED) › Q3 2026 › vs Q2 2026
Medifast (MED) Q3 2026 vs Q2 2026 (quarter over quarter)
Medifast's revenue fell $4.3M (-6%) from $76.4M in Q2 2026 to $72.0M in Q3 2026.
Medifast, Q3 2026: revenue $72.0M (-19% year over year), operating margin -26.9%, net loss $17.5M, operating cash flow $3.3M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 4.0% | 1.0% | +3.0 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $72.0M | $76.4M | −$4.3M | -6% |
| Other income, net | $1.5M | $1.3M | $187K | +14% |
| Income tax benefit | $324K | −$109K | $433K | — |
| Net loss | $17.5M | $3.1M | $14.4M | +465% |
| Costs & expenses | $91.4M | $80.8M | $10.6M | +13% |
| Operating costs | $91.4M | $80.7M | $10.7M | +13% |
| Cost of revenue | $22.0M | $23.0M | −$980K | -4% |
| Operating expenses | $69.4M | $57.7M | $11.7M | +20% |
| Operating cash sources | $20.8M | $4.8M | $16.0M | +334% |
| Depreciation & amortization | $2.4M | $3.4M | −$1.1M | -31% |
| Share-based compensation | $1.9M | $1.8M | $32K | +2% |
| Working capital & other | $16.6M | −$467K | $17.1M | — |
| Net loss absorbed | $17.5M | $3.1M | $14.4M | +465% |
| Operating cash flow | $3.3M | $1.7M | $1.6M | +94% |
| Free cash flow (OCF − capex) | $2.9M | $728K | $2.1M | +294% |
| Capital expenditures | $427K | $969K | −$542K | -56% |
Questions
How much did Medifast's revenue grow quarter over quarter in Q3 2026?
Medifast's revenue fell $4.3M (-6%) from $76.4M in Q2 2026 to $72.0M in Q3 2026.